olsalazine has been researched along with Inflammatory Bowel Diseases in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 14 (66.67) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, T; Li, Y; Liang, X; Lin, H; Liu, F; Otkur, W; Pei, S; Piao, HL; Qi, H; Wang, J; Xiang, K; Yang, R; Zhang, X; Zhou, H | 1 |
| Dhaneshwar, SS | 1 |
| Boulieu, R; Lachaux, A; Le Gall, C; Nguyen, TM | 1 |
| Erichsen, Jv; Hessmann, M; Hoffmeyer, A; Pahl, A; Sann, H | 1 |
| Cummings, JH; Edmond, LM; Hopkins, MJ; Magee, EA | 1 |
| Hessemer, CA; Schinagl, EF | 1 |
| Allgayer, H; Erdmann, E; Kruis, W; Sauerbruch, T; Scheurlen, C | 1 |
| Rasmussen, SN | 1 |
| Axelsson, LG; Bylund-Fellenius, AC; Landström, E | 1 |
| Cosnes, J; Elefant, E; Gendre, JP; Marteau, P; Modigliani, R; Rambaud, JC; Tennenbaum, R | 1 |
| Knoll, U; Schusser, G; Strauhs, P; Ungemach, FR | 1 |
| Allgayer, H; Böhne, P; Gugler, R; Höfer, P; Kruis, W; Schmidt, M | 1 |
| Giaffer, MH; Holdsworth, CD; O'Brien, CJ | 1 |
| Tolia, V | 1 |
| Crouch, R; Davis, AE; Patterson, F | 1 |
| Rijk, MC; van Schaik, A; van Tongeren, JH | 1 |
| Aronson, JK; Crotty, B; Jewell, DP; Rosenberg, WM | 1 |
| Fitton, A; Wadworth, AN | 1 |
| Crotty, B; Dalton, HR; Hoang, P; Jewell, DP | 1 |
| Swartz, ML | 1 |
| Lauritsen, K | 1 |
3 review(s) available for olsalazine and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colon; Fatty Acids, Omega-3; Heparin, Low-Molecular-Weight; Humans; Inflammatory Bowel Diseases; Mesalamine; Phenylhydrazines; Prodrugs; Sulfasalazine | 2014 |
Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Animals; Humans; Inflammatory Bowel Diseases | 1991 |
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Leukotriene B4; Mesalamine; Prostaglandins; Sulfasalazine; Thromboxane B2 | 1989 |
1 trial(s) available for olsalazine and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
Topics: Adult; Aged; Aminosalicylic Acids; Delayed-Action Preparations; Diarrhea; Drug Carriers; Feces; Female; Gastrointestinal Transit; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Middle Aged; Sulfasalazine | 1992 |
17 other study(ies) available for olsalazine and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Aminosalicylates target GPR35, partly contributing to the prevention of DSS-induced colitis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Humans; Inflammatory Bowel Diseases; Mice; Mice, Inbred C57BL; NF-kappa B; Prodrugs; Receptors, G-Protein-Coupled | 2023 |
High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine.
Topics: Adolescent; Aminosalicylic Acids; Azathioprine; Biotransformation; Child; Child, Preschool; Drug Therapy, Combination; Erythrocytes; Female; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Lymphopenia; Male; Mesalamine; Purines; Salicylates; Sulfasalazine | 2010 |
Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Colon; Cyclosporine; Dextran Sulfate; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Mesalamine; Mice; Mice, Inbred BALB C; Receptors, Prostaglandin E, EP4 Subtype; Thioguanine | 2013 |
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
Topics: Amino Acids; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Desulfovibrio; Feces; Fermentation; Fusobacterium; Humans; In Vitro Techniques; Inflammatory Bowel Diseases; Mesalamine; Phenylhydrazines; Sulfasalazine; Sulfides | 2003 |
Desensitization to sulfasalazine.
Topics: Aminosalicylic Acids; Child; Drug Hypersensitivity; Humans; Inflammatory Bowel Diseases; Stevens-Johnson Syndrome; Sulfasalazine | 1993 |
Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?
Topics: Aminosalicylic Acids; Binding, Competitive; Colon, Sigmoid; Diarrhea; Humans; Ileum; Inflammatory Bowel Diseases; Intestinal Mucosa; Mesalamine; Ouabain; Sodium-Potassium-Exchanging ATPase | 1993 |
Bioavailability of controlled release mesalazine (5-ASA) preparations.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Delayed-Action Preparations; Humans; Inflammatory Bowel Diseases; Mesalamine | 1995 |
Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine.
Topics: Aminosalicylic Acids; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Mice; Mice, Inbred BALB C; Mice, Nude; Outcome Assessment, Health Care; Sulfasalazine; Survival Analysis; Treatment Outcome | 1998 |
[Pregnancy outcome in inflammatory bowel diseases].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Crohn Disease; Female; Humans; Inflammatory Bowel Diseases; Mesalamine; Prednisone; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prognosis; Surveys and Questionnaires | 1999 |
Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses.
Topics: Administration, Oral; Aminosalicylic Acids; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Feces; Female; Horse Diseases; Horses; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Prodrugs | 2002 |
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Chromatography, High Pressure Liquid; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Humans; Hydroxides; Hydroxyl Radical; Inflammatory Bowel Diseases; Linoleic Acid; Linoleic Acids; Mesalamine; Spectrophotometry, Ultraviolet; Superoxides | 1992 |
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
Topics: Aminosalicylic Acids; Drug Hypersensitivity; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Phenylhydrazines; Sulfapyridine; Sulfasalazine | 1992 |
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
Topics: Adolescent; Aminosalicylic Acids; Child; Chronic Disease; Desensitization, Immunologic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Stevens-Johnson Syndrome; Sulfasalazine | 1992 |
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Cocarcinogenesis; Colonic Neoplasms; Dimethylhydrazines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Incidence; Inflammatory Bowel Diseases; Male; Mesalamine; Metronidazole; Neoplasm Invasiveness; Rats; Rats, Wistar; Sulfasalazine | 1992 |
Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northern; Cell Line; Depression, Chemical; Dose-Response Relationship, Drug; HLA-DR Antigens; Humans; Inflammatory Bowel Diseases; Interferon-gamma; Mesalamine; Protein Binding; Receptors, Interferon; Tumor Cells, Cultured | 1992 |
Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cell Line; Colchicine; Colon; Epithelium; Flow Cytometry; HLA-DR Antigens; Humans; Inflammatory Bowel Diseases; Interferon-gamma; Male; Mesalamine; Middle Aged; Salicylates | 1992 |
Dipentum (olsalazine sodium)
Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases | 1991 |